Investigating the role of METTL1 in acute myeloid leukemia
The role, mechanism, and therapeutic potential of METTL1 in acute myeloid leukemia
This study is looking at how a protein called METTL1 affects the growth of acute myeloid leukemia (AML) and is testing a new treatment that could help fight this type of cancer by blocking METTL1, which might lead to better options for patients with AML.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11115684 on NIH RePORTER |
What this research studies
This research focuses on understanding how METTL1, an RNA methyltransferase, contributes to the development and progression of acute myeloid leukemia (AML). By utilizing advanced techniques like CRISPR/Cas9 screening, the study aims to identify the dependence of AML cells on METTL1 and explore its potential as a therapeutic target. The researchers have discovered a promising METTL1 inhibitor that shows significant anti-leukemic activity, which could lead to new treatment options for patients with AML. The goal is to develop small-molecule inhibitors that can effectively target and inhibit METTL1's activity, potentially improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have not responded to existing therapies.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results in targeting RNA modifications in cancer, suggesting that this approach could be effective for AML as well.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Su, Rui — Beckman Research Institute/city of Hope
- Study coordinator: Su, Rui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.